accountBiovail struck a deal with Swiss biotech Santhera (SANN.S: Quote) over a drug to treat dyskinesia in Parkinson's disease. The deal cut into Biovail's third-quarter results, as it was forced to absorb some research and development costs. Biovail said it...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Biovail profit lower after R&D charges
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
